Please assess the completion status of the following clinical trial:

Trial Title: Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Is able to provide informed consent.~2. Is over the age of 18 years~3. Has a diagnosis of ulcerative colitis of over 3 months duration that was confirmed by a specialist gastroenterologist~4. Has inflammation limited to 25cm proximal to the anal verge~5. Has failed to achieve remission with, or be intolerant of, the use of conventional therapy defined as oral and/or rectal 5-Aminosalicylates, and/or oral and rectal steroids~6. Has symptoms of active UC with a Mayo score of between 6 and12~7. Medications:~   1. Oral 5-Aminosalicylates: If taking an oral 5-Aminosalicylates the patient has used them continuously for 4 weeks and has been on a stable dose for 2 weeks prior to the screening visit.~  2. Oral Corticosteroids: If taking oral corticosteroids the patient has used them continuously for 4 weeks and has been on a stable dose for 2 weeks prior to the screening visit at a dose of ≤30mg.~  3. Oral Azathioprine/6MP or Methotrexate: If taking one of these medications the patient has used them for a minimum of 12 weeks and has been on a stable dose for 4 weeks prior to screening.~  4. Rectal Preparations; 5-Aminosalicylates and corticosteroids: All rectal preparations have been ceased at least one day prior to Week 0.~8. Has a normal serum potassium levels defined as 3.4-5mmol/L.~9. Has normal renal function defined as a Glomerular Filtration Rate (GFR) \>60ml/min.~10. Willing to participate in the study and comply with the proceedings by signing a written informed consent.~11. Free of any clinically significant disease, other than ulcerative colitis, that would interfere with the study's evaluations.~12. Subjects can understand and is able to adhere to the dosing and visit schedules; Agrees to record symptom severity scores, medication times, adverse events and concomitant medications accurately and consistently.~Exclusion Criteria:~1. Has Crohn's disease.~2. Has colitis extending more than 25cm from the anal verge.~3. Has a known hypersensitivity/allergic reaction to tacrolimus.~4. Is pregnant or is breast-feeding.~5. Has unstable, or poorly controlled, hypertension.~6. Has an abnormal serum potassium level defined as outside the range of 3.4-5mmol/L.~7. Has chronic renal failure defined as a Glomerular Filtration Rate \<60 ml/min.~8. Is currently using a potassium-sparing diuretic agent.~9. Has received a trial medication within 12 weeks of screening.~10. Has documented HIV infection.~11. Has a known malignancy, a pre-malignant lesion, or any history of malignancy within the past 5 years (excluding squamous and/or basal cell carcinomas).~12. Presence of alcoholism, alcoholic liver disease, or other chronic liver disease.~13. Has known dementia and the inability to understand the trial requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rectal tacrolimus (Type: ACTIVE_COMPARATOR): Active medications - Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml 3mls will be applied rectally twice a day
- Rectal Placebo (Type: PLACEBO_COMPARATOR): Placebo 3ml applied rectally twice a day. Identical to Interventional agent expect for the lack of tacrolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).